Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity rates

30 Aug 2025

Abstract excerpt

AIMS: Several international guidelines recommend DPYD genotype-based dosing in patients treated with fluoropyrimidines. This study evaluates the incidences of severe fluoropyrimidine-related toxicity between wild-type patients and DPYD variant allele carriers in a real-world patient cohort. METHODS: This retrospective, observational cohort study was conducted in adult patients with a first fluoropyrimidine-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Cancer Treatment and Pharmacology
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40884356
DOI: 10.1002/bcp.70266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesPMID 40884356Read ↗

Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosingSemantic proximity Read ↗

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with FluoropyrimidinesSemantic proximity Read ↗

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.Semantic proximity Read ↗

Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.Semantic proximity Read ↗

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse eventsSemantic proximity Read ↗

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.Semantic proximity Read ↗

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.Semantic proximity Read ↗

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.Semantic proximity Read ↗

Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.Semantic proximity Read ↗

DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.Semantic proximity Read ↗

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisSemantic proximity Read ↗

Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.